Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Icrucumab, an antibody targeting FLT1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enokizumab, an antibody targeting IL9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Drozitumab, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Carlumab, an antibody targeting CCL2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amatuximab, an antibody targeting MSLN.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Quilizumab, an antibody targeting IgE.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pateclizumab, an antibody targeting LTA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Indatuximab, an antibody targeting SDC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crenezumab, an antibody targeting Amyloid-beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simtuzumab, an antibody targeting LOXL2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Setoxaximab, an antibody targeting Shiga Toxin Type 2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Seribantumab, an antibody targeting HER3.